Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00018070 · ClinicalTrials.gov registry record · Phase 1

Identification and Treatment of Feeder Vessels in Macular Degeneration

A Phase 1 study of Macular Degeneration, sponsored by National Eye Institute (NEI).

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT00018070 is a Phase 1 study of Macular Degeneration that has completed, run by National Eye Institute (NEI). The registered enrollment target is 20 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00018070, a Phase 1 study of Macular Degeneration, has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study will try to identify and treat feeder vessels in age-related macular degeneration. The macula is the part of the retina in the back of the eye that determines central or best vision. In macular degeneration, leaking blood vessels under the macula lead to loss of central vision. These vessels branch out tree-like from one or more feeder vessels. Instead of treating all the abnormal branching vessels, this study will try to find and close only the feeder vessels, thereby depriving the abnormal vessels of nutrition. The vessels will be closed with laser beam treatment. People 50 years of age and older with macular degeneration and visual acuity worse than 20/50 in the study eye and the same or better vision in the other eye may be eligible for this study. Candidates will undergo fluorescein angiography to try to locate feeder vessels. For this procedure, a yellow dye is injected into an arm vein. The dye travels to the blood vessels in the eyes, and pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. Before laser treatment, participants will have a complete eye examination, including measurement of visual acuity, evaluation of the front part of the eye with a slit lamp microscope, examination of the retina with an ophthalmoscope, and measurement of eye pressure using a tonometer. During the laser treatment phase of the study, participants will have indocyanine green angiography-a procedure similar to fluorescein angiography, but using a green dye-to photograph the retina and identify feeder vessels. If feeder vessels are located, laser beam treatment will begin. For this procedure, the eye is anesthetized with numbing drops. A special contact lens is then placed on the eye for the laser treatment. The number of treatments depends on how well the individual patient responds, but usually between two and

Conditions Studied

Interventions

  • PROCEDURE Angiography
  • PROCEDURE Laser Treatment

Study Locations (1)

Maryland

  • National Eye Institute (NEI) - Bethesda

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2001-06-28
Est. Completion 2006-08-30
Phase Phase 1

Sponsor

National Eye Institute (NEI)

221 total trials

What the Registry Record Tells You About NCT00018070

The ClinicalTrials.gov registry entry for NCT00018070 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (89% lower). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Angiography is the first listed.

NCT00018070 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00018070 about?

NCT00018070 is a clinical study titled "Identification and Treatment of Feeder Vessels in Macular Degeneration". This study will try to identify and treat feeder vessels in age-related macular degeneration. The macula is the part of the retina in the back of the eye that determines central or best vision. In macular degeneration, leaking blood vessels under the macula lead to loss of central vision. These vess...

What is the current status of trial NCT00018070?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2001-06-28. Estimated completion is 2006-08-30.

What conditions does trial NCT00018070 study?

This clinical trial studies the following conditions: Macular Degeneration.

What interventions are being tested in trial NCT00018070?

The interventions under investigation include: Angiography (PROCEDURE), Laser Treatment (PROCEDURE).

Who is sponsoring clinical trial NCT00018070?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00018070 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.